title: [Current point of view on medical treatment of unstable angina].
abstract: The combined death/infarct rate in the weeks following unstable angina ranges from 10 to 40%. Aspirin and GP IIb/IIIa antagonists reduce the mortality and morbidity, which has not been demonstrated with heparin. The short term clinical results of treatment with hirudin are better than those with heparin. A rebound biological effect after heparin or hirudin therapy may have adverse clinical consequences. Nitrate derivatives have a role to play and adjuvant therapy includes the betablockers and some calcium antagonists in special indications.
authors.affiliation: Service de soins intensifs, Cliniques Universitaires Saint-Luc, Bruxelles, Belgique.
authors.forename: J
authors.initials: J
authors.lastname: Col
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000789:Angina, Unstable / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D009566:Nitrates / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D009566:Nitrates; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin
vernacular_title: Un point de vue actuel sur le traitement médical de l'angor instable.